The AHA raised concerns that October 2024 federal guidance on Medicare drug price negotiations may allow drugmakers to “wrongly justify fundamental changes to the 340B program.”
AHA Urges CMS to Block Drugmaker 340B Rebate Models, Improve Medicare Transaction Facilitator
A major hospital advocacy group recently warned that October 2024 agency guidance on Medicare drug price negotiations may allow drugmakers [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.